Breast cancer is one of the most rampant forms of cancer today, and is seen as the main threat to life of women. While cancer can occur in men as well, which is frequently observed in women. According to recent statistics, breast cancer affects more women in urban areas than in people living in rural areas. But there is some good news, scientists have discovered a new protein called Erbin, which is believed to be an anti-tumor factor in aggressive breast cancer. One of the first known-oncogenes has a partner protein that helps breast cancer and proliferate when locked, so is cancer. The ErbB2 gene, commonly called HER2 is highly expressed in about 25 percent of breast cancers. Scientists have now discovered protein that is highly expressed in these cancers and essential for the support of breast cancer ErbB2.
When scientists interfered with the interaction between the two in mice, tumor growth and spread to the lungs usual was inhibited. The team documented the expression of more than 171 in both cases of aggressive human breast cancer forms as well.
The findings point to a new therapeutic target for aggressive breast cancer and potentially a supplement for women who become resistant to Herceptin, or trastuzumab, the drug was given to ErbB2 positive patients, said corresponding author Dr. Lin Mei. In addition, Erbin could be a biomarker diagnostic doctors look at breast tissue biopsies.
Mei said yes Erbin could be a new goal: to disrupt interaction and would be therapeutic. Second, when a patient became resistant Herceptin because the extracellular domain of ErbB2 was lost, this approach should still be effective because of the critical interaction of the two.
The Food and Drug Administration approved Herceptin for women with metastatic breast cancer overexpressing ErbB2 or HER2 cancer in 1998 and in 2006, as an adjuvant treatment in early stage HER2-positive breast cancer. The study is published in the journal PNAS .
Image source: Getty
This article was originally published on thehealthsite, Read the original article here